Noxopharm Share Price and Company Fundamentals
Last traded: Today at 10:59 PM
Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region. The company develops Sofra, a platform designed to regulate innate immune signaling with greater precision; and Chroma, a small molecule technology platform focused on the development of multiple drug candidates for cancer treatment. It is also developing SOF-SKN, a topical therapy that has completed Phase I clinical trial for cutaneous lupus erythematosus; and CRO-67, a dual-cell preclinical drug candidate for the treatment of pancreatic cancer. In addition, the company intends to improve mRNA vaccines. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
0.00%
Beta
0.08
Market cap
$11.69M
Enterprise value
$15.34M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.noxopharm.com |
| Mailing address | 60 Linksley Ave Glenhaven NSW 2156 Australia |
| Phone / Fax | 61 2 9144 2223 / |
Dividends
More: Noxopharm Dividend history, yield and payout ratio
Dividend yield
0.00%
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Noxopharm paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.NOX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Nov 2026, following are the company executives and directors listed on Noxopharm.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Olivier Laczka B.S., M.Sc., Ph.D. | Chief Executive Officer | ||
| Mr. Shawn Pieter Van Boheemen FCPA, J.P. | CFO & Company Secretary | ||
| Ms. Jeanette Bell Ph.D. | Chief Operating Officer |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-239.60%
Return on assets
-66.60%
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Noxopharm is 11.69M and its enterprise value is 15.34M. The enterprise value to revenue ratio of NOX is 10.75. The enterprise value to EBITDA ratio of NOX is -4.49.
The NOX's stocks Beta value is 0.08 making it 92% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Noxopharm (NOX)
Noxopharm (ASX:NOX) Frequently Asked Questions
1. What is Noxopharm's Stock Symbol?
Noxopharm trades on ASX under the ticker symbol "NOX".
2. What is Noxopharm's stock price today?
One share of NOX stock can currently be purchased for approximately $0.035.
3. How can I contact Noxopharm?
Noxopharm's mailing address is 60 Linksley Ave Glenhaven NSW 2156 Australia. The company can be reached via phone at 61 2 9144 2223.
4. What is Noxopharm's official website?
The official website of Noxopharm is https://www.noxopharm.com.